Ashley Thorsell, MD
Endocrinology, Diabetes & Metabolism · Santa Barbara, CANPI 1013146364
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $8,014 of the $12,098 with a category attached, or 66.2%. Insulet Corporation accounts for 67.9% of it on its own, with 25 other manufacturers making up the rest.
Across 155 payments — averaging $78.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$8K
- Abbott$539
- Novo Nordisk$500
- Mannkind Corporation$456
- Medtronic$378
- Tandem Diabetes Care, Inc.$358
- plus $2K from 20 others
Across 66 payments — averaging $1921.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Diabetes Care, Inc.$83K
- Abbott$44K
What the payments were for
- Consulting fees$3002%
- Speaking & faculty fees$8,01466%
- Food & beverage$3,50729%
- Education$2782%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 9 | $8,214 |
| Abbott | 10 | $539 |
| Novo Nordisk | 20 | $500 |
| Mannkind Corporation | 26 | $456 |
| Medtronic(2 entities) | 8 | $378 |
| Tandem Diabetes Care, Inc. | 10 | $358 |
| Dexcom, Inc. | 9 | $266 |
| Amgen | 12 | $222 |
| Sanofi-aventis U.S. LLC | 8 | $171 |
| Ascensia Diabetes Care US Inc. | 3 | $162 |
| Boehringer Ingelheim | 7 | $142 |
| AstraZeneca | 9 | $142 |
| Sequel Med Tech, LLC | 4 | $113 |
| Novartis | 2 | $64 |
| Lilly USA, LLC | 3 | $58 |
| Antares Pharma, Inc. | 2 | $52 |
| Companion Medical, Inc. | 1 | $47 |
| Regeneron Healthcare Solutions, Inc. | 2 | $38 |
| AbbVie | 2 | $38 |
| Senseonics, Incorporated | 2 | $26 |
| Cequr Corporation | 1 | $26 |
| Halozyme Inc | 1 | $23 |
| BD | 1 | $16 |
| Merck | 1 | $16 |
| Johnson & Johnson | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$8,154
- Afinion 2$300
- MINIMED 780G$178
- DEXCOM CGM$125
How this compares
$12,098 in reported general payments places this provider in the 80th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 166 | $229,218 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 117 | $127,604 |
| TrulicityDulaglutide | 62 | $89,351 |
| RybelsusSemaglutide | 60 | $88,498 |
| JardianceEmpagliflozin | 82 | $88,430 |
| MounjaroTirzepatide | 80 | $83,122 |
| Tresiba Flextouch U-100Insulin Degludec | 51 | $34,687 |
| Xigduo XrDapaglifloz Propaned/Metformin | 33 | $34,159 |
| Teriparatide | 12 | $31,074 |
| FarxigaDapagliflozin Propanediol | 24 | $26,194 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $24,731 |
| JanuviaSitagliptin Phosphate | 12 | $19,784 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 20 | $15,635 |
| SynjardyEmpagliflozin/Metformin Hcl | 14 | $14,151 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $14,103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $500 | $317,716226 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Synjardy | $142 | $230,185213 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Baqsimi | $58 | $181,373161 claims |
| AstraZenecaFarxiga | $142 | $26,19424 claims |
| MerckJanuvia | $16 | $19,78412 claims |
| AbbVieSynthroid | $38 | $10,261115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Santa Barbara
- Daniel BergerSanta Barbara$541K
- Tricia Westhoff-PankratzSanta Barbara$69K
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.